Cellectis (CLLS) Assets Average (2015 - 2026)
Cellectis (CLLS) recorded quarterly Assets Average of $307.0 million in Q1 2026, down 8.07% quarter-over-quarter from $333.9 million in Q4 2025, and down 17.89% on a YoY basis from $373.8 million in Q1 2025.
Cellectis (CLLS) Assets Average (2015 - 2026) Analysis & Trends
Cellectis' Assets Average history runs 12 years deep, the most recent figure standing at $307.0 million for Q1 2026.
- In Q1 2026, Assets Average fell 17.89% year-over-year to $307.0 million; the TTM figure through Mar 2026 stood at $307.0 million (down 17.89% YoY), while the FY2025 annual figure was $354.1 million, down 1.33% from the prior year.
- Assets Average was $307.0 million for Q1 2026 at Cellectis, down from $333.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $401.5 million in Q3 2024 to a low of $218.7 million in Q3 2023.
- Historically, Assets Average has averaged $323.2 million across 5 years, with a median of $334.0 million in 2022.
- The sharpest annual moves came in 2022 and 2024: Assets Average slumped 31.97% in 2022, then surged 83.6% in 2024.
- A 5-year view of Assets Average shows it stood at $270.4 million in 2022, then advanced by 0.59% to $272.0 million in 2023, then surged by 43.28% to $389.7 million in 2024, then decreased by 14.33% to $333.9 million in 2025, then retreated by 8.07% to $307.0 million in 2026.
- The last three Assets Average figures came in at $307.0 million (Q1 2026), $333.9 million (Q4 2025), and $348.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 33.42 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 795.91 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13.04 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.72 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 26.03 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 40.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 10.06 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.06 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 660.38 Mn |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | 306.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 306.95 Mn |
| Dec 31, 2025 | 333.88 Mn |
| Sep 30, 2025 | 348.51 Mn |
| Jun 30, 2025 | 359.03 Mn |
| Mar 31, 2025 | 373.82 Mn |
| Dec 31, 2024 | 389.71 Mn |
| Sep 30, 2024 | 401.51 Mn |
| Jun 30, 2024 | 380.80 Mn |
| Mar 31, 2024 | 344.36 Mn |
| Dec 31, 2023 | 271.99 Mn |
| Sep 30, 2023 | 218.69 Mn |
| Jun 30, 2023 | 239.54 Mn |
| Mar 31, 2023 | 256.31 Mn |
| Dec 31, 2022 | 270.40 Mn |
| Sep 30, 2022 | 300.23 Mn |
| Jun 30, 2022 | 334.04 Mn |
| Mar 31, 2022 | 364.63 Mn |
| Dec 31, 2021 | 397.48 Mn |
| Sep 30, 2021 | 435.23 Mn |
| Jun 30, 2021 | 450.14 Mn |